ATI PN PHARMACOLOGY LEVEL 3
PROCTORED EXAM 2026/2027
60 Q&As WITH NGN & RATIONALES
Practical Nursing Pharmacology
Verified | 2026/2027 ATI PN Pharmacology Curriculum
Next Generation NCLEX-PN (NGN) Standards
,Key Features
✓ The Rights of medication administration and PN scope of practice
✓ Pharmacokinetics and pharmacodynamics principles for practical nursing
✓ Autonomic nervous system and cardiovascular drug classifications
✓ Antimicrobial agents and adverse effect monitoring
✓ ATI Clinical Judgment Measurement Model (CJMM) application in pharmacology
Updates for 2026
1. Updated FDA black box warnings for high-alert medications and novel
anticoagulants — The Food and Drug Administration has issued revised black box warnings for
high-alert medications including direct oral anticoagulants (DOACs), emphasizing the risk of life-
threatening bleeding and spinal hematoma following neuraxial procedures, requiring practical
nurses to reinforce patient teaching on bleeding precautions, signs of hemorrhage, and strict
adherence to dosing schedules.
2. Revised ATI protocols for insulin and controlled substance administration — ATI
has updated its protocols for insulin administration to incorporate the latest American Diabetes
Association guidelines on sliding scale versus correctional insulin, and has reinforced controlled
substance handling procedures aligned with DEA Title 21 regulations, requiring meticulous
documentation of wasting, two-nurse verification, and chain-of-custody integrity in clinical
settings.
3. New clinical guidelines for managing opioid-induced constipation and overdose
reversal — The 2026 guidelines introduce expanded indications for naloxone co-prescribing
with opioids, updated protocols for managing opioid-induced constipation using peripherally
acting mu-opioid receptor antagonists (PAMORAs), and reinforced training for practical nurses
on recognizing early signs of respiratory depression and administering reversal agents in
community and long-term care settings.
Abstract
This document presents a comprehensive 60-question actual examination designed to assess the
foundational and intermediate pharmacology competencies required for the ATI PN
Pharmacology Level 3 Proctored Exam, as defined by the 2026/2027 ATI Practical Nursing
curriculum and aligned with Next Generation NCLEX-PN (NGN) standards. The questions are
systematically distributed across five core content domains: Pharmacokinetics and
Pharmacodynamics, Medication Administration and Safety, Autonomic and Cardiovascular
Drugs, Antimicrobials and Immune Agents, and Nursing Considerations and Patient Education.
Each question is accompanied by a detailed rationale grounded in current evidence-based
standards for safe medication administration, a systematic explanation of why each distractor is
incorrect, and a specific reference to the 2026 ATI PN Pharmacology Review Module chapter,
FDA guideline, or authoritative nursing textbook section from which the question is derived. The
examination emphasizes the practical application of the ATI Clinical Judgment Measurement
Model (CJMM) to pharmacological decision-making, integrating recognition of cues, analysis of
findings, prioritization of hypotheses, generation of solutions, taking action, and evaluation of
outcomes. The questions reinforce safe medication administration principles, drug classification
recognition, therapeutic and adverse effect monitoring, and patient teaching strategies essential
to the practical nurse scope of practice in diverse clinical settings.
,Keywords
ATI PN Pharmacology, Proctored Exam, Medication Administration, Pharmacokinetics, Drug
Classifications, Nursing Interventions, Patient Education, NCLEX-PN Preparation, Safe
Medication Standards
Content Area Overview
Content Area Questions Key Topics Weight
Pharmacokinetics & 1-12 ADME, half-life, 20%
Pharmacodynamics therapeutic index,
drug interactions
Medication 13-24 10 Rights, dosage 20%
Administration & calculations, high-
Safety alert meds, controlled
substances
Autonomic & 25-38 Adrenergic, 23.3%
Cardiovascular Drugs ACE/ARBs, beta-
blockers, diuretics,
anticoagulants
Antimicrobials & 39-50 Antibiotics, 20%
Immune Agents antifungals,
antivirals, NSAIDs,
immunosuppressants
Nursing 51-60 CJMM, prioritization, 16.7%
Considerations & teaching, age-related,
Patient Education NGN case studies
Examination Questions
Domain: Pharmacokinetics & Pharmacodynamics
Q1. A patient takes an oral medication that undergoes extensive first-pass
metabolism. Which route of administration would bypass the first-pass effect and
increase bioavailability?
A. Sublingual
B. Oral sustained-release
C. Rectal suppository
D. Enteric-coated oral
Correct Answer: A. Sublingual
Rationale: The first-pass effect occurs when a drug is absorbed from the GI tract and passes
through the liver before reaching systemic circulation, significantly reducing bioavailability.
Sublingual administration allows the drug to be absorbed directly into the systemic circulation
through the rich vascular supply under the tongue, completely bypassing hepatic first-pass
metabolism. This results in higher bioavailability compared to oral routes for drugs that
undergo extensive first-pass metabolism.
Why Wrong: Oral sustained-release formulations still pass through the liver via the portal
circulation and are subject to first-pass metabolism. Rectal suppositories partially bypass the
first-pass effect but a significant portion of the drug still drains into the portal circulation via the
, superior rectal vein. Enteric-coated oral tablets only protect the drug from stomach acid; they still
undergo first-pass metabolism once absorbed in the intestines.
Reference: ATI PN Pharmacology Review Module, Chapter 1: Pharmacokinetics
Q2. A patient who is taking warfarin, a highly protein-bound drug, is prescribed a
new medication that is also highly protein-bound. What is the nurse's primary
concern regarding this drug-drug interaction?
A. Increased free warfarin levels leading to increased anticoagulant effect
B. Decreased absorption of both medications from the GI tract
C. Accelerated hepatic metabolism of warfarin
D. Enhanced renal excretion of warfarin
Correct Answer: A. Increased free warfarin levels leading to increased
anticoagulant effect
Rationale: When two highly protein-bound drugs are administered together, they compete for
binding sites on plasma proteins such as albumin. The new drug can displace warfarin from its
protein-binding sites, increasing the concentration of free (unbound) warfarin in the plasma.
This increased free drug level produces a greater pharmacologic effect, which for warfarin
means an elevated risk of bleeding and elevated INR.
Why Wrong: Protein binding displacement does not affect absorption from the GI tract; that
process occurs before the drugs enter systemic circulation. Displacement from protein-binding
sites does not accelerate hepatic metabolism; in fact, the increased free drug may actually saturate
metabolic pathways. Renal excretion is not directly enhanced by protein-binding displacement;
free drug may be cleared faster, but the clinical concern is the transient increase in free drug
activity.
Reference: ATI PN Pharmacology Review Module, Chapter 1: Drug-Drug Interactions
Q3. A patient has been taking phenobarbital for several months. The nurse notes
that the therapeutic effect of another medication the patient takes has diminished.
Which mechanism best explains this finding?
A. Phenobarbital has induced hepatic cytochrome P450 enzymes, increasing metabolism of
the other drug
B. Phenobarbital has inhibited hepatic cytochrome P450 enzymes, decreasing metabolism of
the other drug
C. Phenobarbital has reduced renal blood flow, impairing excretion of the other drug
D. Phenobarbital has altered gastric pH, decreasing absorption of the other drug
Correct Answer: A. Phenobarbital has induced hepatic cytochrome P450 enzymes,
increasing metabolism of the other drug
Rationale: Phenobarbital is a well-known enzyme inducer that stimulates the production of
hepatic cytochrome P450 enzymes, particularly CYP3A4 and CYP2C9. Increased enzyme
activity accelerates the metabolism of concurrently administered drugs that are substrates of
these enzymes, reducing their plasma concentrations and therapeutic effects. This is why
patients on enzyme-inducing drugs often require higher doses of other medications to maintain
therapeutic levels.
Why Wrong: Phenobarbital induces rather than inhibits cytochrome P450 enzymes; inhibition
would increase, not decrease, the other drug's effect. Phenobarbital does not significantly reduce
renal blood flow, and the diminished therapeutic effect is explained by increased metabolism, not
PROCTORED EXAM 2026/2027
60 Q&As WITH NGN & RATIONALES
Practical Nursing Pharmacology
Verified | 2026/2027 ATI PN Pharmacology Curriculum
Next Generation NCLEX-PN (NGN) Standards
,Key Features
✓ The Rights of medication administration and PN scope of practice
✓ Pharmacokinetics and pharmacodynamics principles for practical nursing
✓ Autonomic nervous system and cardiovascular drug classifications
✓ Antimicrobial agents and adverse effect monitoring
✓ ATI Clinical Judgment Measurement Model (CJMM) application in pharmacology
Updates for 2026
1. Updated FDA black box warnings for high-alert medications and novel
anticoagulants — The Food and Drug Administration has issued revised black box warnings for
high-alert medications including direct oral anticoagulants (DOACs), emphasizing the risk of life-
threatening bleeding and spinal hematoma following neuraxial procedures, requiring practical
nurses to reinforce patient teaching on bleeding precautions, signs of hemorrhage, and strict
adherence to dosing schedules.
2. Revised ATI protocols for insulin and controlled substance administration — ATI
has updated its protocols for insulin administration to incorporate the latest American Diabetes
Association guidelines on sliding scale versus correctional insulin, and has reinforced controlled
substance handling procedures aligned with DEA Title 21 regulations, requiring meticulous
documentation of wasting, two-nurse verification, and chain-of-custody integrity in clinical
settings.
3. New clinical guidelines for managing opioid-induced constipation and overdose
reversal — The 2026 guidelines introduce expanded indications for naloxone co-prescribing
with opioids, updated protocols for managing opioid-induced constipation using peripherally
acting mu-opioid receptor antagonists (PAMORAs), and reinforced training for practical nurses
on recognizing early signs of respiratory depression and administering reversal agents in
community and long-term care settings.
Abstract
This document presents a comprehensive 60-question actual examination designed to assess the
foundational and intermediate pharmacology competencies required for the ATI PN
Pharmacology Level 3 Proctored Exam, as defined by the 2026/2027 ATI Practical Nursing
curriculum and aligned with Next Generation NCLEX-PN (NGN) standards. The questions are
systematically distributed across five core content domains: Pharmacokinetics and
Pharmacodynamics, Medication Administration and Safety, Autonomic and Cardiovascular
Drugs, Antimicrobials and Immune Agents, and Nursing Considerations and Patient Education.
Each question is accompanied by a detailed rationale grounded in current evidence-based
standards for safe medication administration, a systematic explanation of why each distractor is
incorrect, and a specific reference to the 2026 ATI PN Pharmacology Review Module chapter,
FDA guideline, or authoritative nursing textbook section from which the question is derived. The
examination emphasizes the practical application of the ATI Clinical Judgment Measurement
Model (CJMM) to pharmacological decision-making, integrating recognition of cues, analysis of
findings, prioritization of hypotheses, generation of solutions, taking action, and evaluation of
outcomes. The questions reinforce safe medication administration principles, drug classification
recognition, therapeutic and adverse effect monitoring, and patient teaching strategies essential
to the practical nurse scope of practice in diverse clinical settings.
,Keywords
ATI PN Pharmacology, Proctored Exam, Medication Administration, Pharmacokinetics, Drug
Classifications, Nursing Interventions, Patient Education, NCLEX-PN Preparation, Safe
Medication Standards
Content Area Overview
Content Area Questions Key Topics Weight
Pharmacokinetics & 1-12 ADME, half-life, 20%
Pharmacodynamics therapeutic index,
drug interactions
Medication 13-24 10 Rights, dosage 20%
Administration & calculations, high-
Safety alert meds, controlled
substances
Autonomic & 25-38 Adrenergic, 23.3%
Cardiovascular Drugs ACE/ARBs, beta-
blockers, diuretics,
anticoagulants
Antimicrobials & 39-50 Antibiotics, 20%
Immune Agents antifungals,
antivirals, NSAIDs,
immunosuppressants
Nursing 51-60 CJMM, prioritization, 16.7%
Considerations & teaching, age-related,
Patient Education NGN case studies
Examination Questions
Domain: Pharmacokinetics & Pharmacodynamics
Q1. A patient takes an oral medication that undergoes extensive first-pass
metabolism. Which route of administration would bypass the first-pass effect and
increase bioavailability?
A. Sublingual
B. Oral sustained-release
C. Rectal suppository
D. Enteric-coated oral
Correct Answer: A. Sublingual
Rationale: The first-pass effect occurs when a drug is absorbed from the GI tract and passes
through the liver before reaching systemic circulation, significantly reducing bioavailability.
Sublingual administration allows the drug to be absorbed directly into the systemic circulation
through the rich vascular supply under the tongue, completely bypassing hepatic first-pass
metabolism. This results in higher bioavailability compared to oral routes for drugs that
undergo extensive first-pass metabolism.
Why Wrong: Oral sustained-release formulations still pass through the liver via the portal
circulation and are subject to first-pass metabolism. Rectal suppositories partially bypass the
first-pass effect but a significant portion of the drug still drains into the portal circulation via the
, superior rectal vein. Enteric-coated oral tablets only protect the drug from stomach acid; they still
undergo first-pass metabolism once absorbed in the intestines.
Reference: ATI PN Pharmacology Review Module, Chapter 1: Pharmacokinetics
Q2. A patient who is taking warfarin, a highly protein-bound drug, is prescribed a
new medication that is also highly protein-bound. What is the nurse's primary
concern regarding this drug-drug interaction?
A. Increased free warfarin levels leading to increased anticoagulant effect
B. Decreased absorption of both medications from the GI tract
C. Accelerated hepatic metabolism of warfarin
D. Enhanced renal excretion of warfarin
Correct Answer: A. Increased free warfarin levels leading to increased
anticoagulant effect
Rationale: When two highly protein-bound drugs are administered together, they compete for
binding sites on plasma proteins such as albumin. The new drug can displace warfarin from its
protein-binding sites, increasing the concentration of free (unbound) warfarin in the plasma.
This increased free drug level produces a greater pharmacologic effect, which for warfarin
means an elevated risk of bleeding and elevated INR.
Why Wrong: Protein binding displacement does not affect absorption from the GI tract; that
process occurs before the drugs enter systemic circulation. Displacement from protein-binding
sites does not accelerate hepatic metabolism; in fact, the increased free drug may actually saturate
metabolic pathways. Renal excretion is not directly enhanced by protein-binding displacement;
free drug may be cleared faster, but the clinical concern is the transient increase in free drug
activity.
Reference: ATI PN Pharmacology Review Module, Chapter 1: Drug-Drug Interactions
Q3. A patient has been taking phenobarbital for several months. The nurse notes
that the therapeutic effect of another medication the patient takes has diminished.
Which mechanism best explains this finding?
A. Phenobarbital has induced hepatic cytochrome P450 enzymes, increasing metabolism of
the other drug
B. Phenobarbital has inhibited hepatic cytochrome P450 enzymes, decreasing metabolism of
the other drug
C. Phenobarbital has reduced renal blood flow, impairing excretion of the other drug
D. Phenobarbital has altered gastric pH, decreasing absorption of the other drug
Correct Answer: A. Phenobarbital has induced hepatic cytochrome P450 enzymes,
increasing metabolism of the other drug
Rationale: Phenobarbital is a well-known enzyme inducer that stimulates the production of
hepatic cytochrome P450 enzymes, particularly CYP3A4 and CYP2C9. Increased enzyme
activity accelerates the metabolism of concurrently administered drugs that are substrates of
these enzymes, reducing their plasma concentrations and therapeutic effects. This is why
patients on enzyme-inducing drugs often require higher doses of other medications to maintain
therapeutic levels.
Why Wrong: Phenobarbital induces rather than inhibits cytochrome P450 enzymes; inhibition
would increase, not decrease, the other drug's effect. Phenobarbital does not significantly reduce
renal blood flow, and the diminished therapeutic effect is explained by increased metabolism, not
